Beam Therapeutics Inc. (BEAM) Prices 16.15M Share Offering at $28.48/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Jones Trading Upgrades Beam Therapeutics Inc (BEAM) to Buy
March 10, 2025 12:59 PM EDTJones Trading analyst Soumit Roy upgraded Beam Therapeutics Inc (NASDAQ: BEAM) from Hold to Buy with a price target of $34.00.
The analyst comments "Model changes: We are raising our POS for AATD to 35% from 15%, increasing our adjusted peak sales to ~$1.9BN in 2036, upgrading our rating to Buy from Hold and a PT of $34. BEAM's in vivo edited AATD data mark an important step for the gene editing space, where effective editing levels were observed. Liver biopsy data in the future would accurately quantify the percent editing, but management mentioned that likely >50%... More
